Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Innovation Is Highest Where It Matters Most, FDA Analysis Shows

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A new system of measuring innovation in new drugs proposed by analysts from FDA’s Office of Planning paints a rational picture of drug development oriented by medical need, with the greatest innovation in serious and life-threatening conditions.

You may also be interested in...



What Innovation Crisis? First-In-Class Drug Approvals Stable For Almost 25 Years, FDA Says

An FDA study evaluating NMEs by level of innovation finds level first-in-class approvals to be consistent, and approvals after the study period reinforce “encouraging” findings. Analysis says new metric should be basis for assessment of programs created by FDASIA to speed development of innovative products.

On The Docket: Recent Submissions For US FDA Approval

Round-up of late summer applications recently submitted to US FDA, adapted from the Pink Sheet FDA Performance Tracker's User Fee Goal Dates chart.

US FDA Oncology Applications: Real-Time Review And Breakthrough Pathway Show Durable Appeal

Recent submissions include what could be the fourth novel agent approved under the RTOR pilot.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel